Form 4: Milton Ault III Reports ALZN Stock Transactions

Sentiment:

Insider Transaction Report 23 September 2025 4:30 PM

Alzamend Neuro Director and 10% owner Milton C. Ault III reported a sale of common stock and a conversion of preferred stock into common shares.

Summary

Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc. (ALZN), filed a Form 4 to report recent transactions.
On September 19, 2025, Ault Lending, LLC, an entity associated with Mr. Ault, sold 77,009 shares of Common Stock at a price of $2.3485 per share.
On September 22, 2025, Ault Lending, LLC, converted 232 shares of Series B Convertible Preferred Stock into 100,000 shares of Common Stock at a conversion price of $2.32 per share.
Following these transactions, Ault Lending, LLC, beneficially owns 108,260 shares of Common Stock and 1,071.2447 shares of Series B Convertible Preferred Stock.
Mr. Ault also indirectly holds 11,068 shares of Common Stock through Ault Life Sciences, Inc., and 61 shares through Ault Life Sciences Fund, LLC, in addition to 1,843 shares held directly.
Ault Lending, LLC, continues to hold Common Stock Purchase Warrants with underlying shares of 13,556, 8,667, and 1,111, all with an exercise price of $108 and various expiration dates in 2029.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including both a sale of common stock and a conversion of preferred stock into common shares, which is neutral in terms of overall company sentiment.

Positives

Ault Lending, LLC, increased its beneficial ownership of common stock by 100,000 shares through the conversion of preferred stock, indicating continued equity exposure.

Negatives

Ault Lending, LLC, sold 77,009 shares of common stock, reducing its direct common stock holdings.

Future Outlook

Industry Context

Related Party Transactions

Ault Lending, LLC, is a wholly-owned subsidiary of Hyperscale Data, Inc., where Mr. Ault is Executive Chairman, and is deemed to have voting and investment power over its securities.
Mr. Ault has sole voting and investment power over securities held by Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC.

Stakeholder Impact

Shareholders: The sale of common stock by a director and 10% owner could be perceived negatively by the market, while the conversion of preferred stock into common stock increases the insider's direct common stock exposure, potentially signaling confidence in the common equity.

Key Dates

Date	Description
01/31/2024	Date Series B Convertible Preferred Stock became exercisable.
08/01/2024	Date Common Stock Purchase Warrants became exercisable.
09/27/2024	Date Common Stock Purchase Warrants became exercisable.
10/30/2024	Date Common Stock Purchase Warrants became exercisable.
09/19/2025	Transaction Date for sale of Common Stock by Ault Lending, LLC.
09/22/2025	Transaction Date for conversion of Series B Preferred Stock by Ault Lending, LLC.
09/23/2025	Signature Date of Milton C. Ault, III.
08/01/2029	Expiration Date for Common Stock Purchase Warrants (exercise price $108).
09/27/2029	Expiration Date for Common Stock Purchase Warrants (exercise price $108).
10/30/2029	Expiration Date for Common Stock Purchase Warrants (exercise price $108).

Recommendation

hold

The filing details a mixed set of insider transactions, including a sale of common stock and a conversion of preferred stock into common shares. While the sale might raise some questions, the conversion increases the insider's common stock exposure. Without further context on the company's performance or strategic direction, these transactions alone do not provide a strong signal for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate for a seasoned investor.

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Insider Trading, Form 4, Stock Sale, Preferred Stock Conversion, Ault Lending, Director, 10% Owner

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.